Clinical Trials Browser

Phase 2 × HER2-positive Breast Cancer × neratinib × Clear all

NCT05154396 2021-12-13

Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer

Phase 2 Unknown

HER2-positive Breast Cancer